MX2015006867A - Composicion farmaceutica novedosa. - Google Patents

Composicion farmaceutica novedosa.

Info

Publication number
MX2015006867A
MX2015006867A MX2015006867A MX2015006867A MX2015006867A MX 2015006867 A MX2015006867 A MX 2015006867A MX 2015006867 A MX2015006867 A MX 2015006867A MX 2015006867 A MX2015006867 A MX 2015006867A MX 2015006867 A MX2015006867 A MX 2015006867A
Authority
MX
Mexico
Prior art keywords
novel pharmaceutical
pharmaceutical composition
dimethyl
trioxo
pyrido
Prior art date
Application number
MX2015006867A
Other languages
English (en)
Inventor
Gossett Campell
Francisco Henriquez
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50828398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015006867(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2015006867A publication Critical patent/MX2015006867A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Se divulgan composiciones farmacéuticas novedosas que contienen solvato de dimetilsulfóxido de N-{3-[3-ciclopropil-5-(2-fluoro-4-y odo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pi rido-[4,3-d]pirimidin-1-il]fenil}acetamida, métodos para usar las composiciones en terapia y procesos para la preparación de las mismas.
MX2015006867A 2012-11-30 2013-11-26 Composicion farmaceutica novedosa. MX2015006867A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731597P 2012-11-30 2012-11-30
PCT/US2013/071816 WO2014085371A1 (en) 2012-11-30 2013-11-26 Novel pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2015006867A true MX2015006867A (es) 2015-10-05

Family

ID=50828398

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006867A MX2015006867A (es) 2012-11-30 2013-11-26 Composicion farmaceutica novedosa.

Country Status (29)

Country Link
US (2) US20150328320A1 (es)
EP (2) EP2925299B1 (es)
JP (1) JP6232443B2 (es)
KR (1) KR102206432B1 (es)
CN (2) CN107970214A (es)
AR (1) AR093648A1 (es)
AU (1) AU2013352369B2 (es)
BR (1) BR112015012111A8 (es)
CA (1) CA2891346A1 (es)
CL (1) CL2015001459A1 (es)
EA (2) EA201791411A1 (es)
ES (1) ES2686730T3 (es)
HK (1) HK1209047A1 (es)
IL (3) IL266415B2 (es)
IN (1) IN2015DN04094A (es)
MA (1) MA38121A1 (es)
MX (1) MX2015006867A (es)
MY (1) MY170427A (es)
NZ (1) NZ628395A (es)
PE (1) PE20151024A1 (es)
PH (1) PH12015501168A1 (es)
PL (1) PL2925299T3 (es)
PT (1) PT2925299T (es)
SG (1) SG11201503688SA (es)
TN (1) TN2015000198A1 (es)
TW (2) TW201434468A (es)
UY (1) UY35157A (es)
WO (1) WO2014085371A1 (es)
ZA (1) ZA201503346B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
US20200178569A1 (en) * 2016-04-29 2020-06-11 Alvin Kershman Method of Coating an Edible Thermoplastic Pet Chew
TW201818936A (zh) 2016-11-25 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種吡啶酮類衍生物醫藥組成物及其製備方法
KR102230721B1 (ko) * 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
JP2022554148A (ja) * 2019-10-22 2022-12-28 ケミストリーアールエックス 表皮及び真皮の過形成を治療するための方法
WO2023219465A1 (ko) * 2022-05-12 2023-11-16 주식회사 지뉴브 안정한 액상 제약 제제

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
ATE383360T1 (de) * 2004-06-11 2008-01-15 Japan Tobacco Inc 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h- pyrido(2,3-d)pyrimidinderivate und verwandte verbindungen zur behandlung von krebs
AU2005313975B2 (en) * 2004-12-07 2012-09-06 Onyx Therapeutics, Inc. Composition for proteasome inhibition
CN1872055A (zh) * 2005-06-01 2006-12-06 李�杰 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法
DK2952197T3 (en) * 2005-10-26 2017-08-07 Cydex Pharmaceuticals Inc SULPHALYCYLETER CYCLE CODE EXTRACTION COMPOSITION AND PROCEDURE FOR PREPARING THEREOF
RS52633B (en) * 2007-01-16 2013-06-28 Bipar Sciences Inc. CANCER TREATMENT FORMULATION
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN101352419B (zh) * 2007-07-26 2010-08-11 天津药物研究院 一种醋溴茶碱无糖型颗粒剂及其制备方法
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
PT3560498T (pt) * 2009-10-16 2022-11-03 Novartis Ag Combinação que compreende um inibidor de mek e um inibidor de b-raf
US9675616B2 (en) 2010-11-11 2017-06-13 Bayer Intellectual Property Gmbh Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
WO2012136776A1 (en) * 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors
CN102600132B (zh) * 2012-03-13 2014-05-14 齐鲁制药有限公司 一种含氨磺必利的口服制剂
CN102626394A (zh) * 2012-03-15 2012-08-08 合肥科大生物技术有限公司 一种精氨酸布洛芬颗粒剂及其制备方法

Also Published As

Publication number Publication date
CN104902876B (zh) 2018-01-19
MY170427A (en) 2019-07-31
EP3400933A1 (en) 2018-11-14
PE20151024A1 (es) 2015-07-27
NZ628395A (en) 2016-10-28
EA028246B1 (ru) 2017-10-31
KR20150091352A (ko) 2015-08-10
IL300664A (en) 2023-04-01
AR093648A1 (es) 2015-06-17
MA38121A1 (fr) 2016-10-31
CA2891346A1 (en) 2014-06-05
IN2015DN04094A (es) 2015-10-09
JP2016501874A (ja) 2016-01-21
EA201591047A1 (ru) 2015-11-30
PL2925299T3 (pl) 2018-11-30
PT2925299T (pt) 2018-10-16
IL266415B1 (en) 2023-11-01
ES2686730T3 (es) 2018-10-19
BR112015012111A8 (pt) 2018-01-23
IL266415B2 (en) 2024-03-01
CL2015001459A1 (es) 2015-12-18
TW201434468A (zh) 2014-09-16
ZA201503346B (en) 2016-01-27
UY35157A (es) 2014-06-30
PH12015501168A1 (en) 2015-08-10
TW201831187A (zh) 2018-09-01
HK1209047A1 (en) 2016-03-24
JP6232443B2 (ja) 2017-11-15
CN104902876A (zh) 2015-09-09
WO2014085371A1 (en) 2014-06-05
EP2925299A1 (en) 2015-10-07
TN2015000198A1 (en) 2016-10-03
EP2925299B1 (en) 2018-06-06
IL238971A0 (en) 2015-07-30
US20150328320A1 (en) 2015-11-19
IL238971B (en) 2019-05-30
AU2013352369A1 (en) 2015-05-28
AU2013352369B2 (en) 2016-07-28
US20170189408A1 (en) 2017-07-06
CN107970214A (zh) 2018-05-01
BR112015012111A2 (pt) 2017-07-11
IL266415A (en) 2019-06-30
KR102206432B1 (ko) 2021-01-22
EP2925299A4 (en) 2016-06-29
EA201791411A1 (ru) 2018-03-30
SG11201503688SA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
JO3594B1 (ar) تركيبة صيدلانية جديدة
PH12015501168A1 (en) Novel pharmaceutical composition
IN2014KN01664A (es)
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
ZA201300002B (en) Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor
PL3515420T3 (pl) Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
MX348823B (es) Formulaciones estables de linaclotida.
PH12015501302A1 (en) Compositions comprising vortioxetine and donepezil
IL233825A (en) H1-indazole-3-carboxamide compounds, preparations containing them and their use in the preparation of medicines
MX2014008390A (es) Formulaciones de romidepsina y sus usos.
IL222780A0 (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
IL266898B (en) Solid powder preparations, a process for their preparation, their formulations and their use
CO6781490A2 (es) Nueva composición farmacéutica
IL218801A (en) Combination containing n - {3 - [3 - cyclopropyl - 5 - (2 - fluoro - 4 - iodo - phenylamino) 6,8 - dimethyl - 2, 4, 7 - trioxo - 3, 4, 6, 7 - tetrahydro - 2 h - Pyrido [4, 3 – d] pyrimidine – 1 – yl] phenyl} acetamide, and n - {(1s) –2– amino-1 - [(3-fluorophenyl) methyl] ethyl} –5-chloro-4 - (4-Chloro-1-Methyl-1H-Pyrazole-5-Yl) -2-Theophenecarboxamide
ZA201500411B (en) Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process
EP2863899B8 (en) Formulations for the preparation of immediate-release tablets for oral use containing low-dose mifepristone for the treatment of endometriosis, tablets thus obtained and their preparation process